BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc.

  • About
    • Overview
    • Management Team
    • Board of Directors
    • Strategic Advisors
  • Product Pipeline
    • Overview
    • Expanded Access
  • News & Media
    • Press Releases
    • Publications
    • Events
    • Media
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Overview
    • Press Releases
    • Press Coverage
    • IR Calendar
    • Email Alerts
    • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Business Development
  • Careers
    • Overview
    • Job Openings
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications
  • Events
  • Media

BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

Nov 14, 2019

BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast

Nov 7, 2019

BioXcel Therapeutics to Present at the 26th Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2019

BioXcel Therapeutics Highlights Upcoming Major Milestones

Oct 10, 2019

BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

Sep 26, 2019

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

Sep 25, 2019

BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices

Sep 18, 2019

BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)

Sep 4, 2019

BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501

Aug 20, 2019

BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Aug 6, 2019
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...15
    © 2021 BioXcel Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap